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Abstract
Ductal carcinoma in situ (DCIS) is a noninvasive precursor
lesion to invasive breast carcinoma. We still have no under-
standing on why only some DCIS lesions evolve to invasive
cancer whereas others appear not to do so during the life span
of the patient. Here, we performed full exome (tumor vs.
matching normal), transcriptome, and methylome analysis of
30 pure high-grade DCIS (HG-DCIS) and 10 normal breast
epithelial samples. Sixty-two percent of HG-DCIS cases dis-
played mutations affecting cancer driver genes or potential
drivers. Mutations were observed affecting PIK3CA (21% of
cases), TP53 (17%), GATA3 (7%), MLL3 (7%) and single cases
of mutations affecting CDH1, MAP2K4, TBX3, NF1, ATM, and
ARID1A. Signiﬁcantly, 83% of lesions displayed numerous
large chromosomal copy number alterations, suggesting they
might precede selection of cancer driver mutations. Integrated
pathway-based modeling analysis of RNA-seq data allowed us
to identify two DCIS subgroups (DCIS-C1 and DCIS-C2) based
on their tumor-intrinsic subtypes, proliferative, immune scores,
and in the activity of speciﬁc signaling pathways. The more
aggressive DCIS-C1 (highly proliferative, basal-like, or ERBB2þ)
displayed signatures characteristic of activated Treg cells
(CD4þ/CD25þ/FOXP3þ) and CTLA4þ/CD86þ complexes
indicative of a tumor-associated immunosuppressive phenotype.
Strikingly, all lesions showed evidence of TP53 pathway inacti-
vation. Similarly, ncRNA and methylation proﬁles reproduce
changes observed postinvasion. Among the most signiﬁcant ﬁnd-
ings, we observed upregulation of lncRNA HOTAIR in DCIS-C1
lesions and hypermethylation of HOXA5 and SOX genes. We
conclude that most HG-DCIS lesions, in spite of representing a
preinvasive stage of tumor progression, displayed molecular
proﬁles indistinguishable from invasive breast cancer. Cancer Res;
75(18); 3980–90. 2015 AACR.
Introduction
Ductal carcinoma in situ (DCIS) is by deﬁnition a precursor
lesion to invasive ductal carcinoma (IDC). The routine use of
screening mammography has led to a dramatic increase in DCIS
detection during the last four decades (1).More than 62,000 cases
per year account for about 25%ofnewbreast cancers in theUnited
States (1). Early retrospective studies concluded that women with
biopsy provenDCIS haveover a 10-fold higher risk for developing
invasive carcinoma than women without DCIS history (2). If left
untreated, it has been estimated that at least one-third of DCIS
cases are likely to progress to IDCduring the lifetime of the patient
(1, 3). Regardless, it is beyond debate that the vast majority of
IDCs results from the progression of precursor DCIS lesions (3).
DCIS lesions are usually classiﬁed as either high-grade (HG-DCIS)
or low-grade (LG-DCIS). Such distinction has limited impact on
clinical management, as most patients with DCIS regardless of
grade still receive similar treatment, which is either total mastec-
tomy or segmental resection with radiation therapy (4–6). Recent
studies argued that it is possible to identify more indolent DCIS
lesions based on a small gene expression panel (Oncotype DX
DCIS; ref. 7); however, concerns have been raised on the useful-
ness of such test and further validation is required (8, 9). Nev-
ertheless, there is a great clinical need to identify those patients
who can be spared radiation therapy after segmental resection, as
it has been argued that many patients do not beneﬁt from this
likely overtreatment (10, 11).
Our current understanding of DCIS is that these are heteroge-
neous lesions and just like invasive carcinoma, DCIS lesions can
be separated into different intrinsic subtypes on the basis of gene
expression features (12–15). Mutations affecting genes such as
TP53 and PIK3CA were also reported in DCIS (16, 17). However,
as reviewed by Polyak, molecular signatures predictive of invasive
progression have not been deﬁned (18). In other words, we still
have no understanding on why only some DCIS lesions evolve to
invasive cancer whereas others appear not to do so. Importantly,
no study to date has comprehensively delineated the molecular
landscape of DCIS at the mutational, transcriptomic, and epige-
netic levels in the same lesions and these are in part major goals of
the present study.
Materials and Methods
Samples
Thirty fresh-frozen pure HG-DCIS cases with matched normal
adjacent breast tissue samples were obtained from the MDACC
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Breast Tumor Bank. Normal breast tissue is deﬁned as grossly
unremarkable breast parenchyma away from the area of DCIS
identiﬁed by imaging studies and gross evaluation and conﬁrmed
by subsequent histologic evaluation. These areas usually selected
at least 1 cm and more away from the lesions. Patient tissue
samples were collected after proper informed consents were
obtained and protocols approved by ethical and institutional
review boards. Ten cosmetic normal mammoplasty specimens
were obtained from the Cooperative Human Tissue Network.
Normal breast epithelial organoids were freshly isolated from the
normal mammoplasty specimens as was previously described by
us (19) and used for identiﬁcation of differentially expressed
genes (DEG) and differentiallymethylated genes (DMG) between
normal and HG-DCIS samples.
DNA from 29 of 30 (97%) pure HG-DCIS samples and their
paired normal breast tissue samples (total 58 samples) were
subjected to exome capture sequencing analysis (Exome-Seq).
DNA from24of 30 (80%)HG-DCIS samples and 5 normal breast
organoids (total 29 samples) were subjected to reduced repre-
sentation bisulﬁte sequencing analysis (RRBS). RNAs from 25 of
30 (83%) pure HG-DCIS and 10 normal breast organoids (total
35 samples) were subjected to RNA sequencing analysis (RNA-
Seq; see Supplementary Table S1).
Histopathologic and immunohistochemical analysis
Histopathologic analysis of tumors and lymphocytic inﬁltrates
were performed on hematoxylin and eosin (H&E)-stained sec-
tions. Intratumor-inﬁltrating lymphocytes (iTIL) are deﬁned as
intraepithelial mononuclear cells within DCIS cell nests or in
direct contact with cells (intralobular stroma) and are reported as
the percentage of the tumor epithelial nests that contain inﬁltrat-
ing lymphocytes. Stromal tumor-inﬁltrating lymphocytes (sTIL)
are deﬁned as the percentage of tumor stroma area that contains
lymphocytic inﬁltrates without direct contact to DCIS cells. All
samples were analyzed for estrogen receptor (ER)/progesterone
receptor (PR) by immunohistochemistry using standard
procedures.
Exome-Seq analysis
DNA from 29 DCIS samples and their paired normal breast
tissue samples (n ¼ 58 samples) were puriﬁed using the DNeasy
Blood and Tissue Kit (Qiagen). Only DNA samples with 260/280
ratios greater than 2.0 were processed for library construction
using the SPRIworks Fragment Library Kit I (Beckman Coulter).
Four libraries were pooled together and processed for exome
capture using the NimbleGen SeqCap EZ Human Exome Library
v3.0 (HG19, Roche), covering more than 23,000 genes and ~64
Mbp, 76-nt paired-end sequencing was performed using an Illu-
mina HiSeq2000 platform at our Department's NGS Facility.
Image analysis, base-calling, and error calibrationwere performed
using Illumina's Genome analysis pipeline. Sequencing was per-
formed reaching an average depth of 40 per sample. Sequenced
76-bp tags were aligned against the human reference genome
(hg19) using BWA v0.7.3 and marked for duplicates using Picard
v1.88 (http://picard.sourceforge.net/). Recalibration of base qual-
ity and indel realignment was performed using the GATK v2.4
(20). Subsequently, single-nucleotide variants (SNV) were iden-
tiﬁed using MuTect v1.1.4 (21). Identiﬁed variants were anno-
tated using ANNOVAR (22), ﬁltered by functional consequence,
and only nonsynonymous and splicing variants were selected. In
addition, we usedControl-FREEC software to detect copy number
alterations and LOH regions in DCIS samples on the basis of
Exome-Seq data (23).
RRBS analysis
We analyzed by RRBS a total of 5 normal breast epithelial
samples and 24 DCIS samples. DNA libraries were prepared for
RRBS at the MDACC's DNA Methylation Core Facility and sub-
jected tonext-generation sequencing (NGS). Short read sequences
were mapped to the human reference genome 19 by Bismark, a
program tomapbisulfate-treated sequencing reads to a genomeof
interest and perform methylation calls in a single step (24). Raw
datasets have been submitted to NCBI GEO database with acces-
sion number GSE69994. Promoter regions were calculated on the
basis of RefSeq gene annotations, such that the region starts 2-kb
upstream of the annotated transcription start site and extends to
500 downstream of the transcription start site (TSS). CpG islands
were downloaded from UCSC genome annotation database
assembled by NCBI (hg19). CpG shores were deﬁned as 2,000-
bp ﬂanking regions on upstream and downstream of a given CGI.
To identify differentiallymethylated sites, ﬁrst we ﬁltered samples
on the basis of read coverage  20. And the signiﬁcant differen-
tially methylated CpGi (DMC) sites were identiﬁed when the
difference of methylation percentages between normal breast
epithelia and DCIS were greater than 0.25 and q < 0.01.
RNA-Seq analysis
RNA was isolated and puriﬁed using TRIzol reagent (Life
Technologies) and RNeasy mini kit (Qiagen). RNA concentration
and integrity were measured on an Agilent 2100 Bioanalyzer
(Agilent Technologies). Only RNA samples with RNA integrity
values (RIN) above 8.0 were considered for subsequent analysis.
mRNA from normal breast epithelial samples and DCIS samples
were processed for directional mRNA-Seq library construction
using the ScriptSeq v2 RNA-Seq Library Preparation Kit (Epicen-
tre) according to the manufacturer's protocol. We performed 76-
nt paired-end sequencing using an Illumina HiSeq2000 platform
and obtained about 40 million tags per sample. The short
sequenced reads were mapped to the human reference genome
(hg19)by the splice junction aligner TopHat (25).Weused several
R/Bioconductor packages to accurately calculate the gene expres-
sion abundance at the whole-genome level using the aligned
records (BAM ﬁles) and to identify differentially expressed genes
between normal and DCIS samples. Brieﬂy, the number of reads
mapped to each gene on the basis of the UCSC.hg19.KnownGene
database were counted, reported, and annotated using the Geno-
micFeatures, Rsamtools, and org.Hs.eg.db packages. Raw datasets
have been submitted to NCBI GEO database with accession
number GSE69994. To identify differentially expressed genes
between normal breast epithelium and DCIS samples, we used
the edgeR-test on the basis of the normalized number of reads
mapped to each gene (26).
Pathway-based analysis was performed using the PARADIGM
software at the Five3 Genomics server (default options; discreti-
zation bounds of 33%) on the basis of the normalized gene
expression proﬁles of the deregulated transcripts between normal
and DCIS samples [false discovery rate (FDR) < 0.01; log fold
change (FC)  1] expressed in log2 counts per million (27).
PARADIGM produces a data matrix of integrated pathway activ-
ities (IPA), this data matrix was used in place of the mRNA
expression proﬁles to identify the topmost variable IPAs among
samples. Heatmap visualization of differentially expressed
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transcripts and IPAs were done with the MultiExperiment Viewer
software (MeV v4.9; ref. 28). Intrinsic subtype classiﬁcation of
DCIS samples into luminal-like, basal-like, ERBB2-enriched, and
normal-like groups was performed using the 50-gene (PAM50)
predictor bioclassiﬁer R script (29). We used the ESTIMATE
algorithm (Estimation of STromal and Immune cells inMalignant
Tumors using Expression data) to infer the immune and stromal
components from each DCIS sample (30).
Bioinformatic analysis of the The Cancer Genome Atlas-BRCA
dataset
To perform a comparative analysis of the mutational, gene
expression,methylation, andpathway activities proﬁles identiﬁed
in DCIS with invasive stages, we analyzed invasive breast cancer
(IBC) datasets obtained from the The Cancer Genome Atlas
(TCGA)-BRCA project (31). The clinical (including PAM50 sub-
types fromRNAseq) and preprocessed data (IBC gene-level muta-
tion, IBC gene expression Illumina HiSeq, IBC DNA methylation
450K and IBC Paradigm RNAseq þ CNV proﬁles) were retrieved
from the Cancer Genomics Browser (https://genome-cancer.soe.
ucsc.edu/) and cBioPortal (http://www.cbioportal.org/). Data
integration and visualizationwere donewith R andMeV software,
respectively.
Results and Discussion
Fresh-frozen pure DCIS samples are extremely difﬁcult to
obtain, as all tumor materials are submitted for routine histo-
pathologic evaluationwith formalin ﬁxation and parafﬁn embed-
ding. Only cases with available frozen tissue samples are usually
those from large palpable DCIS cases, which tend to beHG-DCIS.
Nevertheless, we were able to gather from our Institution's breast
tumorbank a groupof fresh-frozen "pure"HG-DCIS samples (i.e.,
with no evidence of invasion in the same breast) and matching
normal pairs and subjected them to a thorough characterization
involving whole Exome-Seq, RRBS, and RNA-Seq. We also gen-
erated RNA-Seq and RRBS data from breast epithelial organoids
obtained from normal mammoplasty specimens for identiﬁca-
tion of differentially expressed genes and differential methylated
genes between normal and DCIS lesions.
Signiﬁcantly mutated genes and DNA copy number variations
in DCIS
Exome-Seq data on 29 pure DCIS normal matched pairs
indicated a median of 75% targeted genome loci having at least
40 coverage. We detected 2,908 single-base substitutions,
including 1,324 nonsynonymous (missense) SNVs, 46 stop
gain, 2 stop loss, 16 mutations at splicing sites, 151 noncoding
RNA (ncRNA) mutations, and 1,369 SNVs encoded synony-
mous (silent) mutations (Fig. 1A; Supplementary Table S2).
Almost 50% of these mutations were C>T:G>A transitions in
agreement with the previously described most prevalent muta-
tion-type signature in breast cancer (Fig. 1A; ref. 32). We also
detected 24 frameshift deletions, 10 frameshift insertions, and
43 non-frameshift deletion/insertion events. Every single DCIS
displayed a signiﬁcant number of mutations. The total muta-
tion rate was 1.61 mutations per Mbp on average with a range
of 0.8 to 3.8 mutations per Mbp (Fig. 1B), indicating that some
DCISs have quite higher mutation rates than others. We iden-
tiﬁed somatic mutations affecting at least 10 genes reported as
mutated at a 2% rate in IBC (33). In total, 18 of 29 HG-DCIS
cases (62%) displayed mutations affecting one or combina-
tions of targets described as cancer driver genes or potential
drivers. Among these, we detected mutations affecting PIK3CA
(21%), TP53 (17%), GATA3 (7%),MLL3 (7%) and single cases
of mutations affecting CDH1, MAP2K4, TBX3, NF1, ATM, and
ARID1A (Fig. 1B). The comparative frequency of mutations of
these genes in pure DCIS and the TCGA database on IBC (n ¼
976 cases as per September 2014) is shown in Fig. 1C. Similarly
to IBC previous gene mutation data (31, 33), the most fre-
quently mutated genes are PIK3CA (6 cases; 4 of them affecting
ER/PR-positive cases) and TP53 (5 cases; 4 of them affecting ER/
PR-negative cases). Only one case displayed mutations in both
genes. Interestingly, several genes reported as mutated in IBC,
such asMAP3K1, PTEN, AKT1, RUNX1, RB1, and various others
so far, have not been detected mutated in DCIS, suggesting that
perhaps some of these mutations may be associated with
postinvasion events; however, our sample number is still lim-
ited. In summary, we observed that 100% of pure HG-DCIS
display numerous somatic mutations, but only a subgroup
display mutations affecting cancer driver genes or potential
drivers. Nevertheless, the mutational proﬁle in pure HG-DCIS
is extremely similar to that observed at invasive stages with only
a moderate lower frequency of mutation for cancer driver genes.
As we performed RNA-Seq in parallel, the identiﬁed mutations
were validated by allele-speciﬁc RNA-Seq data.
Somatic copy number variations (CNV) were estimated using
Exome-Seq data to predict regions of genomic alterations such as
ampliﬁcation, gains, and losses (23). Figure 1D summarizes the
overall frequency of DNA gains/losses affecting all chromosome
arms among DCIS samples. The proﬁle of copy number changes
across the genome in HG-DCIS is practically identical to proﬁles
reported in invasive breast lesions (34) and is in agreement with
early observations using comparative genome hybridization
(CGH) approaches (35). In our approach, however, we were able
to deﬁne with more precision the genomic regions spanning the
CNV (Supplementary Table S2). The most common regions of
increased DNA copy number include chr1q, chr8q, chr17q,
and chr20q and regions of common copy number loss include
regions chr8p, chr11q, chr17p, and chr22q (Fig. 1D; Supplemen-
tary Fig. S1 and Supplementary Table S2). Regions of potential
focal ampliﬁcationwere also identiﬁed, including ERBB2,VEGFA,
MYC, AURKA,MDM2, FGFR1, and CCND1 (Fig. 1B and Supple-
mentary Table S2).
Among the most important conclusions of the CNV analysis
is that 83% (24 of 29) of DCIS lesions displayed evidence of
large chromosomal alterations; only in 5 samples (T9, T15,
T28, T30, and T31), large chromosomal copy number changes
were not detected (Supplementary Table S2). Interestingly,
multiple cases (T2, T4, T5, T10, T13, T16, T22, and T24)
displayed signiﬁcantly large chromosomal copy number altera-
tions but no mutations in known cancer driver genes, whereas
16 of 18 cases (89%) with mutations in cancer driver genes all
show signiﬁcant chromosomal copy number alterations (Fig.
1B; Supplementary Table S2). Importantly, in only 3 of 29
(10%) HG-DCIS (T9, T15, T28), no large chromosomal abnor-
malities or mutations in putative cancer driver genes were
detected. Nevertheless our ﬁndings also suggest that large
chromosomal copy number alterations (trisomies, monoso-
mies, large chromosomal duplications, and deletions) occur
early in tumor progression, perhaps preceding the selection of
alleles with mutations in driver genes.
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Gene expression analysis of coding RNAs
Whole-transcriptome unsupervised analysis from RNA-Seq
data demonstrates a clear segregation of normal breast epithelium
and DCIS samples on the basis of similarity distances (measured
in leading logFC) from dimension 1 in a multidimensional
scaling plot (MDS; Fig. 2A). More importantly, DCIS samples
were clustered into two subgroups (cluster 1 or DCIS-C1 and
cluster 2 or DCIS-C2) according to the positive and negative
distances from MDS dimension 2.
We observed that the ER/PR status determined by immuno-
histochemistry and their intrinsic subtypes predicted by using the
50-gene PAM50 model (29) were signiﬁcantly associated with
Figure 1.
Mutations and copy number alterations in DCIS samples. A, types of single-base substitutions and InDels identiﬁed by Exome-Seq analysis. B, driver and co-driver
mutations in DCIS samples. Each column represents one DCIS case and each row represents the number of mutations in each gene per tumor. Blue squares, þ
mutation. Genes shown with an asterisk are rarely mutated in IBC (2%); however, they are noted as possible co-drivers events, as they are found either
in the SANGER Cancer Gene Census database or have signiﬁcant potentially carcinogenic biological functions. C, comparative frequency of mutations of
driver/co-driver mutations in pure DCIS (red bars) and the TCGA database on IBC (blue bars). D, CNVs among DCIS samples. Chromosomal gains (red, up)
and losses (green, down) as percentage of occurrence in the respective region are indicated.
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each identiﬁedDCIS cluster (P< 0.001). Sixty-seven percent of the
cases in DCIS-C1 were ER/PR double negative and basal-like or
ERBB2þ with high proliferative scores. On the other hand, 100%
of the cases in DCIS-C2 were ER/PR double positive, luminal-like
with low/moderate proliferative scores (Fig. 2B).
Statistical analysis of RNA-Seq data revealed 5,985 transcripts
differentially expressed between normal and DCIS samples (FDR
< 0.01; logFC  1), 95% were coding RNAs and 5% were
ncRNAs. Among the deregulated genes, 885 were differentially
expressed between both DCIS clusters (FDR < 0.01; logFC  1;
Supplementary Table S3). To identify bioprocesses that differen-
tiateDCIS-C1 from theDCIS-C2,weperformed functional enrich-
ment andpathway activity analyses. Gene ontology (GO) analysis
of deregulated transcripts between DCIS clusters revealed speciﬁc
functional modules characteristic for each of both subgroups: a
functional module strongly related to immune (P < 1.46E35)
and inﬂammatory (P < 6.4E19) responses clearly associated to
the DCIS-C1 group and amodule related with response to steroid
Figure 2.
Transcriptome analysis of normal and DCIS samples. A, multidimensional scaling plot showing the distance of each sample from each other determined by their
leading logFC. The leading logFC is a distance metric that represents the average (root mean square) of the largest absolute logFC between each pair of samples.
B, prediction of DCIS intrinsic subtypes based on the PAM50 gene model based on RNA-Seq proﬁles. All normal samples (not included in the heatmap) were
classiﬁed as the normal-like subtype. C, functional enrichment analysis of the differentially expressed genes between DCIS clusters. D, box and whisker plots
display increased iTIL (left) and immune scores determined by the ESTIMATE (30) algorithm (right) for the DCIS-C1 group comparedwith DCIS-C2 group and normal
samples. E, heatmap of DCIS-C1 and DCIS-C2 differentially expressed transcripts among the IBC subtypes obtained from the TCGA breast cancer database.
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hormones (P < 9.1E4) associated to the DCIS-C2 group (Fig. 2C
and Supplementary Fig. S2). In addition, functional annotation
analysis identiﬁed "T-cell differentiation", "B-cell activation",
"angiogenesis," "negative regulation of apoptosis," and "ECM
remodeling" to be highly associated with DCIS-C1 -modulated
genes. Given the aforementioned strong association with
immune-related themes, we performed a blind evaluation of
lymphocytic inﬁltrates on H&E sections of all DCIS samples
determining iTIL and sTIL scores. Supporting the GO and func-
tional annotation observations, DCIS-C1 samples showed a sig-
niﬁcantly higher number of iTILs (P < 0.01) than the DCIS-C2
counterparts. Similarly, a gene expression signature–based meth-
od known as ESTIMATE (30) predicted higher immune scores on
DCIS-C1 versus DCIS-C2 (P < 0.001; Fig. 2D).
Further analysis of the behavior of the 885 deregulated tran-
scripts that discriminate both DCIS clusters within the TCGA
breast cancer dataset demonstrated that a large number of genes
(80%) identiﬁedas upregulated in theDCIS-C1group remained
upregulated in basal-like and ERBB2þ breast cancers compared
with the luminal A/B subtypes (Fig. 2E). This is in itself very
signiﬁcant, and similarly to the above described mutational and
CNV analyses, it indicates that most of the gene expression
changes characteristic of IBC are already present at the pure DCIS
(preinvasive) stage.
Pathway-based representation analysis (PARADIGM; ref. 27) of
deregulated transcripts identiﬁed aplethora of signaling pathways
that differ in their activity between normal and DCIS samples,
such as AP1, TNF, TP53, FOXM1, MYB, and E2F1/DP1 pathways
(Fig. 3A; Supplementary Table S3). It was striking to observe
that the TP53 signaling pathway was found deactivated in all
DCIS samples analyzed regardless of TP53mutation status, ER/PR
expression status or intrinsic subtype when compared with nor-
mal epithelium (Fig. 3B). Since on the basis of mutational
evidence is currently believed that TP53 inactivation is mostly
a feature of the basal-like intrinsic subtype (31, 33), we were
surprised by our ﬁnding, thus we decided to perform a pathway-
based analysis focused on the TP53 pathway exclusively in the
existing TCGA IBC dataset. Interestingly, PARADIGM analysis
based on TCGA-BRCA RNA-Seq and CNV proﬁles predict that
TP53 pathway inactivation is a common theme affecting well
above 85% of breast cancers regardless of intrinsic subtypes (and
as consequence also regardless of TP53 mutation status; Supple-
mentary Fig. S3). Nevertheless, this novel information on TP53
pathway inactivation inmost breast cancers should be taken with
caution and requires further validation.
In the DCIS-C2 cases, the activity of the E2/ERa pathway was
the predominant signature (Supplementary Fig. S2), whereas in
the DCIS-C1 subgroup, the HES1 and HIF1A/ARNT pathways
were more frequently activated. Interestingly, the HIF1A/ARNT
was previously identiﬁed as one of the key regulatory features
associated with basal-like carcinomas (31).
More importantly, PARADIGM analysis identiﬁed that 80% of
DCIS-C1 cases showed activity of Treg cells (CD4þ/CD25þ/
FOXP3þ) and CTLA4þ/CD86þ complexes (Fig. 3C). These results
are revealing, as a growing body of evidence indicates that the
outcome of an immune response toward a tumor is largely
determined by the speciﬁc characteristics of the inﬁltrating lym-
phocytes. A tumor-directed immune response involving cytolytic
CD8þ T cells, T-helper 1 cells (Th1), and natural killer (NK) cells
appears to protect against tumor development and progression,
whereas activation of humoral immunity involving B cells and/or
Th2 response appears associated to protumorigenic phenotypes
(36). Suppression of antitumor immune response by inducing T-
cell anergy due Th2-polarized activity and/or expansion of Treg
cells (CD4þCD25þFOXP3þ) with a subsequent loss of T-cell–
mediated cytotoxicity, together with the development of angio-
genesis and tissue remodeling could be instrumental for promot-
ing the progression ofHG-DCIS to the inﬁltrating stages. Recently,
Kristensen and colleagues (37) suggested that the perturbation in
the immune response and IL signaling (IL4, IL6, IL12, and IL23)
can lead to classiﬁcation of IBC subclasses with prognostic value.
Patients who have basal-like breast carcinomas are characterized
Figure 3.
Pathway activities analysis in DCIS
samples versus normal mammary
epithelium. A, PARADIGM inferences of
the most variable integrated pathway
activities using the normalized gene
expression proﬁles of the deregulated
transcripts between normal and DCIS
samples. B, TP53 pathway activity was
found systematically deactivated in
both DCIS groups compared with
normal epithelium (P < 0.001).
C, PARADIGM analysis identiﬁed
increased activities of Treg cells
(CD4þ/CD25þ/FOXP3þ) and
CTLA4þ/CD86þ complexes in DCIS-C1
compared with DCIS-C2 samples
(P < 0.01).
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by high expression of protumorigenic Th2/humoral-related genes
and a low Th1/Th2 ratio. In addition, the immune response and IL
signaling identiﬁed in IBC appears also prominent in DCIS (37).
Importantly, the IPA described in our study indicates that DCIS-
C1 lesions are characterized by a tumor-associated immunosup-
pressive phenotype, suggesting a protumorigenic polarization of
the immune response. In other words, DCIS-C1 lesions bear all
the immunomodulatory characteristic of invasive breast lesions,
thus indicating that the host immune defenses (tumor rejection
responses) have been or are in the process of being defeated.
Gene expression analysis of noncoding RNAs
RNA-Seq analysis allowed us to identify 193 long noncoding
RNAs (lncRNA) as differentially expressed between normal
and DCIS samples (P < 0.01, FDR < 0.01), 127 of which were
antisense RNAs and 66 were long intergenic noncoding RNAs
(lincRNA; Fig. 4A and B). Eighty-seven percent of the identiﬁed
lncRNAs (168 of 193) were upregulated in DCIS (Supplementary
Table S4). Interestingly, 46 of the 127 antisense RNAs and 18 of
the 66 lincRNAs have been recently identiﬁed as potentially
relevant in breast cancer (38). The Genomic Regions Enrichment
of Annotations Tool (GREAT) resource was used to evaluate the
correlation between deregulated lncRNAs and their neighboring
genes (39). We found that 52% of the mRNA genes in the vicinity
of the affected lncRNAs were also deregulated (Supplementary
Table S4), andmost of them (80%) showed a positive association
with the expression of the lncRNAs, which would indicate that
deregulation of cis-acting lncRNA prevails in DCIS. Among the
deregulated lnRNAs in DCIS, we found HOTAIR (HOX transcript
antisense RNA; logFC¼þ5.03; FDR¼ 1.92E8) andHOTAIRM1
(HOXA transcript antisense RNA myeloid–speciﬁc 1; logFC¼1.90;
FDR ¼ 8.63E7; Fig. 4C). HOTAIR and HOTAIRM1 expression
levels were positively correlated with the expression of their
adjacent HOXC (located at chr12q13.13) and HOXA (located at
chr7q15.2) gene clusters, respectively (Fig. 4D). Recent studies
have shown that lncRNAs can be associated with enhancer
regions, leading to increased activity of neighboring genes
(40). One of the best-known lncRNAs, HOTAIR, found signif-
icantly upregulated in DCIS-C1 lesions, was suggested to pro-
mote breast cancer metastasis and shown to be pervasively
overexpressed in most human cancers when tumor tissue was
compared with adjacent noncancerous tissue (41). HOTAIR
interacts with and recruits the Polycomb-repressive complex 2
(PRC2) and regulates chromosome occupancy of EZH2 (a
subunit of PRC2), which leads to histone H3 lysine 27 tri-
methylation of the HOXD locus and subsequent silencing of
this gene cluster. On the other hand, HOTAIRM1, found sig-
niﬁcantly downregulated in many DCIS lesions (particularly
DCIS-C1), was shown to play a role in the regulation of gene
expression during retinoic acid–induced myeloid differentia-
tion preventing the induction of HOXA genes (42). Mechanis-
tically, our data indicate that HOTAIR and HOTAIRM1 may
act by modulating HOX gene expression in trans and cis
during early stages of breast cancer progression. This is the
ﬁrst study demonstrating that these lncRNAs are deregulated
"early" at preinvasive stages of breast cancer progression. The
remaining lncRNAs (LINC00277, LINC00861, LINC00578,
LINC00426, and others shown in Supplementary Table S4)
would constitute a novel group of lncRNAs deregulated in the
transition normal DCIS.
In addition, we were able to identify 36 differentially expressed
pri/pre-miRNAs among the deregulated noncoding transcripts
between normal and DCIS as well. We detectedMIR3606 (logFC
¼ þ6.58),MIR4728 (logFC ¼ þ4.25), andMIR503HG (logFC ¼
þ2.91) among the most upmodulated small noncoding RNAs in
DCIS samples. Interestingly, MIR4728 was speciﬁcally upmodu-
lated in DCIS-C1 samples (logFC ¼ þ2.28). MIR4728 gene is
located at chr17q12 and encoded within intron 24 of the ERBB2
gene (43). Recently, Newie and colleagues demonstrated that
ERBB2 ampliﬁcationmight lead to ESR1 downregulation through
internal seed interaction with miR-4728-3p in breast cancer
cells (44). We corroborate this observation identifying a positive
Figure 4.
Gene expression proﬁle of
deregulated lncRNAs. A, pie chart
displaying the types of lncRNAs
differentially expressed between
normal and DCIS samples. B, heatmap
of deregulated lncRNAs where black
lines on the right indicate potentially
relevant transcripts in IBC as was
determinedbySu and colleagues (38).
C, box and whisker plots representing
HOTAIR and HOTAIRM1 expression
levels among normal and DCIS
samples. D, transcriptomic
coexpression analysis using HOTAIR
and HOTAIRM1 as templates
identiﬁed signiﬁcant positive
correlations with the expression
of their neighboring HOXC
(located at chr12q13.13) and HOXA
(located at chr7q15.2) gene
clusters, respectively (r > 0.7 and
P < 0.0001).
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correlation between ERBB2 and MIR4728 expression (r ¼ 0.90;
P < 0.01) in DCIS samples in agreement with the CNV data.
On the other hand, MIR4260 (logFC ¼ 4.62), MIRNA221
(logFC ¼ 3.55), MIR22/MIR22HG (logFC ¼ 2.34), MIR3661
(logFC¼2.07), andMIR17HG (logFC¼1.94), among others,
were detected as downmodulated in DCIS samples. The human
MIR22 gene is located in a minimal LOH region on chromosome
17 close toTP53.MIR22has been reported tobe downregulated in
hepatocellular, lung, colorectal, ovarian and breast cancer, acting
as a tumor suppressor (45). Furthermore, MIR22 overexpression
induces growth suppression and senescence-like phenotypes in
human breast epithelial and breast cancer cells (46).MIR17HG is
the host gene for the MIR17-20 cluster (a group of at least six
miRNAs) located at 13q31 that function as a tumor suppressor in
human breast cancer by decreasing AIB1 and cyclinD1 expression
(47). The MIR17-20 cluster is known to inhibit breast cancer
cellular proliferation through G1–S cell-cycle arrest (48). Our
study suggests that gain and loss of expression of key regulatory
miRNAs in normal breast epitheliummight constitute important
early procarcinogenic events conducive to overcome the barrier
imposed by senescence and limited cell proliferation. However,
further studies on the proﬁling of the mature miRNAs in normal
and DCIS samples are needed to corroborate the aforementioned
observations.
DNA methylation analysis
RRBS data analysis coupled with RNA-Seq proﬁling allowed us
to identify the most relevant methylation events associated to the
development ofDCIS lesions.We identiﬁed1,103DMCsbetween
normal breast epithelia and DCIS samples (Supplementary Table
S5), mapping at distal (8% at 4 kb to 2 kb relative to TSS),
proximal promoter regions (56% at 2 kb to þ500 bp) or the
gene body (36% at þ500 to þ2 kb) of 311 loci (Fig. 5A). Among
these 1,103 DMC, 1,029 were hypermethylated and 74 were
hypomethylated CpGi sites in DCIS samples. Functional enrich-
ment analysis of the hypermethylated regions in DCIS identiﬁed
Figure 5.
Analysis of differentially methylated CpGi among normal and DCIS samples determined by RRBS. A, distribution of 1,103 differentially methylated CpGi regions
between normal and DCIS samples mapping at distal (4 kb to 2 kb relative to TSS), proximal promoter regions (2 kb to þ500 bp), or the gene body (þ500
to þ2 kb). B, functional enrichment analysis of differentially methylated CpGi regions. C, heatmap of CpGi hypermethylated and downregulated genes
in DCIS samples. D, HOXA5 CpGi methylation proﬁle in normal and DCIS groups in a promoter region spanning from 285 to 560 bp relative to TSS. HOXA5
methylation (E) and expression proﬁles (F) among normal and IBC from the TCGA breast cancer dataset.
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"regulation of transcription/RNA pol II activity," "cell fate com-
mitment/morphogenesis," and "regulation of cell proliferation
and differentiation" as the predominant associated biologic pro-
cesses (Fig. 5B). Furthermore, we identiﬁed 137 DMC for which
mRNA abundance was inversely correlated in DCIS samples
(Supplementary Table S5). Sixteen genes were highly hyper-
methylated and downmodulated in DCIS compared with normal
epithelium (Fig. 5C). Some of the most hypermethylated CpGi
regions were located at the promoters of three SOX family mem-
bers (SOX10, 15, and 17) and the HOXA5 gene. SOX10, SOX15,
and SOX17 are novel HMG box–containing tumor suppressors
involved in a variety of developmental processes that can act as
antagonists to the Wnt/b-catenin signaling pathway (49–51).
These three SOX genes were systematically hypermethylated and
transcriptionally downregulated in almost all DCIS samples com-
pared with normal samples. In agreement with these ﬁndings,
gene expression analysis of these SOX genes in the TCGA dataset
showed a signiﬁcant downmodulation in IBC compared with
normal samples (Supplementary Fig. S4). In a recent study, it was
shown that the SOX10 protein is predominantly expressed in
basal-like breast carcinomas compared with the other subtypes
(52). However, TCGA data analysis clearly showed that SOX10
was downmodulated in luminal-like and ERBB2þ breast cancer
subtypes compared with normal tissue samples (Supplemen-
tary Fig. S4). Fu and colleagues (50) demonstrated that silenc-
ing of SOX17 due to promoter hypermethylation is frequent in
invasive carcinomas and may contribute to aberrant activation
of Wnt signaling in breast cancer. This evidence raises the
possibility that hypermethylation of speciﬁc SOX family mem-
bers could constitute common important epigenetic phenom-
ena occurring at early stages of breast cancer development that
deserves further study.
Interestingly, in our dataset, HOXA5 hypermethylation was
more frequently associated with the DCIS-C1 group, charac-
terized by the presence of tumors with basal-like/ERBB2 intrin-
sic subtypes (Fig. 5D). TP53 gene expression has been shown to
be under the control of HOXA5 in breast cancer cells (53).
Reduced HOXA5 protein levels correlate with the lack of p53
expression, supporting the concept that HOXA5 may act as a
tumor suppressor via activation of p53 expression. HOXA5 has
also been shown to be a strong positive regulator of PR (54). It
is also important to note that 4 of 5 cases with TP53 non-
synonymous mutations were detected in ER/PR double nega-
tive tumors from the DCIS-C1 group (T3, T7, T26, and T29).
Overall, these data suggest that TP53 mutation and HOXA5
hypermethylation could constitute early events during breast
cancer progression that can cooperate to inactivate the TP53
pathway in more prone to progress DCIS lesions. In addition
our pathway-based analysis indicated that TP53 pathway inac-
tivation is an extremely common feature in practically all HG-
DCIS lesions and HOXA5 methylation could be one of the
more relevant causative mechanisms. CpGi methylation and
expression analysis from the TCGA breast cancer dataset dem-
onstrated that HOXA5 hypermethylation and downregulation
can be also identiﬁed and is common in more advanced stages
of breast cancer progression (Fig. 5E and F).
Concluding Remarks
Comprehensive characterization of pure HG-DCIS lesions at
the genome, transcriptome, and methylome levels allowed us to
identify themost relevant changes occurring at a preinvasive stage
of breast cancer progression. A comparison of the mutation and
chromosomal copy number alteration proﬁles identiﬁed in
these pure in situ lesions with previous observations reported
by the TCGA study on IBC, revealing expected similarities with
IBC (e.g., PIK3CA, TP53, GATA3). However, it was striking to
observe that practically all known major genomic abnormali-
ties are already present at preinvasive stages at high frequency
mutation rates and 83% of lesions displaying very large copy
number chromosomal alterations. In only 10% of lesions we
did not detect large chromosomal changes or mutations in so-
called cancer driver genes. More importantly, at the transcrip-
tional level, pathway-based analysis pointed to TP53 pathway
inactivation as extremely common in DCIS regardless of tumor
intrinsic subtype. We also observed that deregulation of genes
associated with the suppression of the antitumor immune
response are hallmarks of a HG-DCIS subgroup (highly pro-
liferative basal-like or ERBB2þ tumors), displaying proﬁles very
similar to those found at invasive and metastatic stages. In
addition, we identiﬁed novel and relevant regulatory circuits
signiﬁcantly deregulated in DCIS that were not previously
reported and that involve coding and noncoding transcripts
(e.g., HOTAIR, HOTAIRM1). Our comprehensive catalogue of
differentially expressed genes is also consistent with the exis-
tence of the most common breast cancer subtypes, but now we
show that these important and complex epigenetic changes,
such as hypermethylation of HOXA5 and speciﬁc SOX genes,
are already operating at the in situ stage. Our ﬁndings clearly
indicate that a subgroup of HG-DCIS lesions can be identiﬁed
displaying more aggressive molecular proﬁles, more impor-
tantly however is that most, if not all, HG-DCIS lesions dis-
played proﬁles indistinguishable from IBC.
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